Search
Delamanid
go.drugbank.com/drugs/DB11637ApprovedInvestigationalDelamanid is an anti-tuberculosis agent derived from the nitro-dihydro-imidazooxazole class of compounds that inhibits mycolic acid synthesis of bacterial cell wall . It is used in the treatment of multidrug-resistant and extensively dru...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesArtenimol
go.drugbank.com/drugs/DB11638ApprovedInvestigationalArtenimol is an artemisinin derivative and antimalarial agent used in the treatment of uncomplicated Plasmodium falciparum infections [FDA Label]. It was first authorized for market by the European Medicines Agency in October 2011 in com...
Categories: Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2D6 InhibitorsVinflunine
go.drugbank.com/drugs/DB11641ApprovedInvestigationalVinflunine is a third-generation member of the vinca alkaloid family with anti-tumour actions. It was first described in 1998 at the Pierre Fabre research center in France. Like other vinca agents, vinflunine is an anti-mitotic agent tha...
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesPitolisant
go.drugbank.com/drugs/DB11642ApprovedInvestigationalPitolisant is a selective antagonist or inverse agonist of the histamine H3 receptor used to treat type 1 or 2 narcolepsy. Narcolepsy is a chronic neurological disorder that affects 1 in 2,000 individuals and is characterized by excessiv...
Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 CYP2B6 InducersCurcumin
go.drugbank.com/drugs/DB11672ApprovedInvestigationalCurcumin, also known as diferuloylmethane, is an active component in the golden spice turmeric (Curcuma longa) and in Curcuma xanthorrhiza oil. It is a highly pleiotropic molecule that exhibits antibacterial, anti-inflammatory, hypoglyce...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesFruquintinib
go.drugbank.com/drugs/DB11679ApprovedInvestigationalFruquintinib is a novel small-molecule anti-VEGFR that targets VEGFR-1,-2, and -3 to inhibit angiogenesis. Tumor angiogenesis is one of the most critical biological processes for increasing oxygen and nutrient supply to cancer cells, and...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 SubstratesVoclosporin
go.drugbank.com/drugs/DB11693ApprovedInvestigationalLupus nephritis (LN) is a type of glomerulonephritis occurring in patients with systemic lupus erythematosus (SLE). LN is a significant cause of renal failure, morbidity, and death in patients with SLE. Within 10 years of being diagnosed...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesPacritinib
go.drugbank.com/drugs/DB11697ApprovedInvestigationalMyelofibrosis (MF) is a rare disorder characterized by hematopoietic abnormalities and fibrosis within the bone marrow. The underlying cause of primary MF is unknown, but secondary MF can arise in patients with a history of polycythemia ...
Categories: Cytochrome P-450 CYP1A2 Inducers, P-glycoprotein inhibitorsAcalabrutinib
go.drugbank.com/drugs/DB11703ApprovedInvestigationalTo date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administer...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsEncorafenib
go.drugbank.com/drugs/DB11718ApprovedInvestigationalEncorafenib, also known as BRAFTOVI, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP...
Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP2B6 Inducers